Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 5/20 | 0.74 |
| ▸ | RAB9A | P51151 | 5/20 | 0.74 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.74 |
| ▸ | PKM | P14618 | 1/20 | 0.74 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.74 |
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.71 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.71 |
| ▸ | GAA | P10253 | 1/20 | 0.71 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.71 |
| ▸ | DHODH | Q02127 | 2/20 | 0.69 |
| ▸ | KLF5 | Q13887 | 2/20 | 0.67 |
| ▸ | HTT | P42858 | 1/20 | 0.67 |
| ▸ | DCLK1 | O15075 | 1/20 | 0.64 |
| ▸ | FES | P07332 | 1/20 | 0.64 |
| ▸ | PIM1 | P11309 | 1/20 | 0.64 |
| ▸ | CDK2 | P24941 | 1/20 | 0.64 |
| ▸ | GSK3A | P49840 | 1/20 | 0.64 |
| ▸ | GSK3B | P49841 | 1/20 | 0.64 |
| ▸ | IRAK1 | P51617 | 1/20 | 0.64 |
| ▸ | MAP4K2 | Q12851 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17770554 | 0.86 | MAPT (0.77) | NPC1RAB9AL3MBTL1PKMPAX8 | |
| SCHEMBL6766057 | 0.86 | NPC1 (1.00) | NPC1RAB9AL3MBTL1PKMPAX8 | |
| SCHEMBL1353347 | 0.84 | KDM4E (0.74) | NPC1RAB9AL3MBTL1PKMPAX8 | |
| SCHEMBL19566127 | 0.84 | KDM4E (0.60) | NPC1RAB9AL3MBTL1PKMPAX8 | |
| SCHEMBL17770342 | 0.83 | DHODH (0.76) | NPC1RAB9AL3MBTL1PKMPAX8 | |
| SCHEMBL12980644 | 0.83 | SMN1; SMN2 (0.64) | NPC1RAB9AKDM4ERXFP1ALDH1A1 | |
| SCHEMBL17770410 | 0.83 | KDM4E (0.69) | NPC1RAB9AL3MBTL1PKMPAX8 | |
| SCHEMBL17770327 | 0.83 | KDM4E (0.69) | NPC1RAB9AL3MBTL1PKMPAX8 | |
| SCHEMBL17770434 | 0.83 | KDM4E (0.58) | NPC1RAB9AL3MBTL1PKMPAX8 | |
| SCHEMBL4911825 | 0.82 | DHODH (1.00) | NPC1RAB9AL3MBTL1PKMPAX8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1680431-A1 | BENZOTHIAZOLE AND THIAZOLE'5,5-B!PYRIDINE COMPOSITIONS AND THEIR USE AS UBIQUITIN LIGASE INHIBITORS | Rigel Pharmaceuticals, Inc. (US) | 2006-07-19 | — | — | EP | claimed |
| US-20050130974-A1 | Benzothiazole compositions and their use as ubiquitin ligase inhibitors | RIGEL PHARMACEUTICALS, INC. | 2005-06-16 | — | — | US | claimed |
| WO-2005037845-A1 | BENZOTHIAZOLE AND THIAZOLE[5,5-B] PYRIDINE COMPOSITIONS AND THEIR USE AS UBIQUITIN LIGASE INHIBITORS | RIGEL PHARMACEUTICALS, INC. (US) | 2005-04-28 | — | — | WO | claimed |
| US-20170319516-A1 | NOVEL MITOCHONDRIAL UNCOUPLERS FOR TREATMENT OF METABOLIC DISEASES AND CANCER | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY | 2017-11-09 | — | — | US | disclosed |
| US-20170319516-A1 | NOVEL MITOCHONDRIAL UNCOUPLERS FOR TREATMENT OF METABOLIC DISEASES AND CANCER | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY | 2017-11-09 | — | — | US | disclosed |
| US-20170319516-A1 | NOVEL MITOCHONDRIAL UNCOUPLERS FOR TREATMENT OF METABOLIC DISEASES AND CANCER | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY | 2017-11-09 | — | — | US | disclosed |
| EP-3220904-A1 | NOVEL MITOCHONDRIAL UNCOUPLERS FOR TREATMENT OF METABOLIC DISEASES AND CANCER | Rutgers, the State University of New Jersey (US) | 2017-09-27 | — | — | EP | disclosed |
| WO-2016081599-A1 | NOVEL MITOCHONDRIAL UNCOUPLERS FOR TREATMENT OF METABOLIC DISEASES AND CANCER | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2016-05-26 | — | — | WO | disclosed |
| WO-2016081599-A1 | NOVEL MITOCHONDRIAL UNCOUPLERS FOR TREATMENT OF METABOLIC DISEASES AND CANCER | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2016-05-26 | — | — | WO | disclosed |
| US-20080039629-A1 | Benzothniazole compositions and their use as ubiquition ligation inhibitors | RIGEL PHARMACEUTICALS, INC. (US) | 2008-02-14 | — | — | US | disclosed |
| US-20080039629-A1 | Benzothniazole compositions and their use as ubiquition ligation inhibitors | RIGEL PHARMACEUTICALS, INC. (US) | 2008-02-14 | — | — | US | disclosed |
| US-20080039629-A1 | Benzothniazole compositions and their use as ubiquition ligation inhibitors | RIGEL PHARMACEUTICALS, INC. (US) | 2008-02-14 | — | — | US | disclosed |
| US-20050130974-A1 | Benzothiazole compositions and their use as ubiquitin ligase inhibitors | RIGEL PHARMACEUTICALS, INC. | 2005-06-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050130974-A1 | Benzothiazole compositions and their use as ubiquitin ligase inhibitors | UBQLN1, UBE2T, NEDD4 | NPC1 1713/4885RAB9A 3792/4885L3MBTL1 2479/4885 |
| US-20080039629-A1 | Benzothniazole compositions and their use as ubiquition ligation inhibitors | UBQLN1, NEDD4, UCHL5 | NPC1 3462/4885RAB9A 3771/4885L3MBTL1 2137/4885 |
| US-20170319516-A1 | NOVEL MITOCHONDRIAL UNCOUPLERS FOR TREATMENT OF METABOLIC DISEASES AND CANCER | HADHA, HADHB, TFAM | NPC1 2642/4885RAB9A 2841/4885L3MBTL1 2154/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.